Century Therapeutics Inc
IPSC0.547USD
+0.015+2.88%
Market hours （ET）Quotes delayed by 15 min
47.14MMarket Cap
LossP/E TTM
More Details of Century Therapeutics Inc Company
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-102, CNTY-107, CNTY-104, and CNTY-106. Its CNTY-101 is focused on targeting CD19 for relapsed, refractory B-cell lymphoma. CNTY-102 targets CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-107 is used of the treatment of solid tumors expressing Nectin-4. CNTY-106 is a multi-specific collaboration program for multiple myeloma.
Company Info
Ticker SymbolIPSC
Company nameCentury Therapeutics Inc
IPO dateJun 17, 2021
CEODr. Brent Pfeiffenberger, Pharm.D.
Number of employees140
Security typeOrdinary Share
Fiscal year-endJun 17
Address25 N 38Th Street, 11Th Floor
CityPHILADELPHIA
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code19104
Phone12159814000
Websitehttps://www.centurytx.com/
Ticker SymbolIPSC
IPO dateJun 17, 2021
CEODr. Brent Pfeiffenberger, Pharm.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Brent Pfeiffenberger, Pharm.D.
Dr. Brent Pfeiffenberger, Pharm.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
449.41K
-0.11%
Mr. Douglas Carr, CPA
Mr. Douglas Carr, CPA
Interim Chief Financial Officer
Interim Chief Financial Officer
423.87K
-1.14%
Dr. Gregory (Greg) Russotti, Ph.D.
Dr. Gregory (Greg) Russotti, Ph.D.
Chief Technology and Manufacturing Officer
Chief Technology and Manufacturing Officer
380.21K
-0.14%
Dr. Chad Cowan, Ph.D.
Dr. Chad Cowan, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
230.31K
+9.25%
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
98.94K
--
Dr. Kimberly Lynn Blackwell, M.D.
Dr. Kimberly Lynn Blackwell, M.D.
Independent Director
Independent Director
--
--
Ms. Daphne E. Quimi, CPA
Ms. Daphne E. Quimi, CPA
Independent Director
Independent Director
--
--
Mr. Timothy P. (Tim) Walbert
Mr. Timothy P. (Tim) Walbert
Independent Director
Independent Director
--
--
Dr. Carlo Rizzuto, Ph.D.
Dr. Carlo Rizzuto, Ph.D.
Independent Director
Independent Director
--
--
Mr. Joseph S. (Joe) Jimenez
Mr. Joseph S. (Joe) Jimenez
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Brent Pfeiffenberger, Pharm.D.
Dr. Brent Pfeiffenberger, Pharm.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
449.41K
-0.11%
Mr. Douglas Carr, CPA
Mr. Douglas Carr, CPA
Interim Chief Financial Officer
Interim Chief Financial Officer
423.87K
-1.14%
Dr. Gregory (Greg) Russotti, Ph.D.
Dr. Gregory (Greg) Russotti, Ph.D.
Chief Technology and Manufacturing Officer
Chief Technology and Manufacturing Officer
380.21K
-0.14%
Dr. Chad Cowan, Ph.D.
Dr. Chad Cowan, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
230.31K
+9.25%
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
98.94K
--
Dr. Kimberly Lynn Blackwell, M.D.
Dr. Kimberly Lynn Blackwell, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 23
Updated: Wed, Jul 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bayer AG
14.71%
Versant Ventures
14.12%
Fujifilm Holdings Corp
8.07%
Bain Capital Life Sciences Investors, LLC
6.28%
Casdin Capital, LLC
3.73%
Other
53.09%
Shareholders
Shareholders
Proportion
Bayer AG
14.71%
Versant Ventures
14.12%
Fujifilm Holdings Corp
8.07%
Bain Capital Life Sciences Investors, LLC
6.28%
Casdin Capital, LLC
3.73%
Other
53.09%
Shareholder Types
Shareholders
Proportion
Corporation
22.78%
Investment Advisor
19.45%
Venture Capital
17.07%
Hedge Fund
9.17%
Investment Advisor/Hedge Fund
4.47%
Individual Investor
3.28%
Research Firm
0.33%
Bank and Trust
0.06%
Pension Fund
0.06%
Other
23.33%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
183
66.08M
76.69%
-11.95M
2025Q1
190
67.80M
85.48%
-12.38M
2024Q4
199
74.05M
87.09%
-5.74M
2024Q3
197
77.29M
91.61%
-2.73M
2024Q2
195
76.53M
90.84%
+3.21M
2024Q1
192
59.55M
90.31%
-4.03K
2023Q4
185
53.19M
83.25%
-1.66M
2023Q3
177
52.18M
87.54%
-4.25M
2023Q2
185
53.42M
89.72%
-5.97M
2023Q1
180
53.68M
91.04%
-5.87M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bayer AG
12.68M
14.71%
--
--
Apr 15, 2025
Versant Ventures
12.17M
14.12%
+714.10K
+6.24%
Apr 15, 2025
Fujifilm Holdings Corp
6.96M
8.07%
--
--
Apr 15, 2025
Bain Capital Life Sciences Investors, LLC
5.41M
6.28%
--
--
Mar 31, 2025
Casdin Capital, LLC
3.21M
3.73%
-1.98M
-38.11%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.74M
3.18%
-34.03K
-1.23%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.59M
3.01%
+60.87K
+2.40%
Mar 31, 2025
VR Adviser, LLC
2.50M
2.9%
-1.46M
-36.87%
Mar 31, 2025
The Vanguard Group, Inc.
2.38M
2.76%
-4.21K
-0.18%
Mar 31, 2025
Dafna Capital Management, LLC
1.70M
1.98%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 Covered Call ETF
0%
Dimensional US Core Equity 1 ETF
0%
Schwab U.S. Small-Cap ETF
0%
Avantis US Equity ETF
0%
iShares Russell 2000 Value ETF
0%
Avantis US Small Cap Equity ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
iShares Russell 3000 ETF
0%
View more
ProShares Hedge Replication ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
Avantis US Equity ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
